Table I.
Correlation between pAkt and pErk1/2 expression, and the clinicopathological parameters in breast cancer patients.
| pAkt expression | pErk1/2 expression | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| Parameter | Patients, n | −, n (%) | +, n (%) | P-valuea | −, n (%) | +, n (%) | P-valuea |
| Age, years | 0.054 | 1.000 | |||||
| ≤50 | 132 | 73 (55.3) | 59 (44.7) | 88 (66.7) | 44 (33.3) | ||
| >50 | 124 | 84 (67.7) | 40 (32.3) | 82 (66.1) | 42 (33.9) | ||
| Tumor size, cm | 0.886 | 0.460 | |||||
| ≤2 | 70 | 42 (60.0) | 28 (40.0) | 44 (62.9) | 26 (37.1) | ||
| >2 | 184 | 113 (61.4) | 71 (38.6) | 125 (67.9) | 59 (32.1) | ||
| Lymph node involvement | 0.020b | 0.286 | |||||
| 0 | 111 | 77 (69.4) | 34 (30.6) | 78 (70.3) | 33 (29.7) | ||
| ≥1 | 143 | 78 (54.5) | 65 (45.5) | 91 (63.6) | 52 (36.4) | ||
| Histological grade | 0.038b | 0.624 | |||||
| I | 18 | 14 (77.8) | 4 (22.2) | 11 (61.1) | 7 (38.9) | ||
| II | 146 | 80 (54.8) | 66 (45.2) | 96 (65.8) | 50 (34.2) | ||
| III | 63 | 44 (69.8) | 19 (30.2) | 45 (71.4) | 18 (28.6) | ||
| ER | 0.365 | 0.592 | |||||
| 0 | 146 | 93 (63.7) | 53 (36.3) | 95 (65.1) | 51 (34.9) | ||
| 1–3 | 109 | 63 (57.8) | 46 (42.2) | 75 (68.8) | 34 (31.2) | ||
| PR | 0.519 | 0.894 | |||||
| 0 | 139 | 88 (63.3) | 51 (36.7) | 92 (66.2) | 47 (33.8) | ||
| 1–3 | 116 | 68 (58.6) | 48 (41.4) | 78 (67.2) | 38 (32.8) | ||
| HER2 | 0.414 | 0.676 | |||||
| 0–1 | 156 | 93 (59.6) | 63 (40.4) | 105 (67.3) | 51 (32.7) | ||
| 2–4 | 90 | 59 (65.6) | 31 (34.4) | 58 (64.4) | 32 (35.6) | ||
| Chemotherapy resistance | 0.564 | 0.016a | |||||
| Yes | 32 | 18 (56.2) | 14 (43.8) | 15 (46.9) | 17 (53.1) | ||
| No | 224 | 139 (62.1) | 85 (37.9) | 155 (69.2) | 69 (30.8) | ||
a
Determined by χ2 test;
b
P<0.05.
pAkt, phosphorylated Akt; pEkr1/2, phosphorylated extracellular-regulated kinase 1/2; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor.